State Share Of Neurontin Settlement Will Fund Comparative Efficacy Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
State attorneys general sharing in the Pfizer Neurontin off-label promotion settlement plan to spend $28 mil. to fund comparative efficacy studies for prescription drug products